PipelineReview.com - Biosimilar Antibodies & Proteins

Show Cart

Biosimilar Antibodies & Proteins

Results 1 - 10 of 30

Jul 2023 Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

Jul 2023 Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Jul 2023 Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

Jul 2023 Adalimumab (Humira) Biosimilars Pipeline Review

Jun 2023 Ranibizumab (Lucentis) Biosimilars Pipeline Review

Jun 2023 Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

Jun 2023 Aflibercept (Eylea) Biosimilars Pipeline Review

Jun 2023 Ustekinumab (Stelara) Biosimilars Pipeline Review

Mar 2023 2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Dec 2019 Competitor Analysis: Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More

Start
Prev
1
2
3
Next
End

Shopping cart

Cart empty

Latest report

c-Met-Targeted Antibody Therapy Pipeline Review

Featured Products

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

CD40 Agonists & CD40/L Antagonists Pipeline Review

Shopping cart

Cart empty

Latest report

c-Met-Targeted Antibody Therapy Pipeline Review

Featured Products

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

CD40 Agonists & CD40/L Antagonists Pipeline Review

La Merie Biologics

FREE Weekly News Bulletin

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing